Advertisement
Research Article

Succession in the Gut Microbiome following Antibiotic and Antibody Therapies for Clostridium difficile

  • Gregory L. Peterfreund,

    Affiliation: Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

    X
  • Lee E. Vandivier,

    Affiliation: Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

    X
  • Rohini Sinha,

    Affiliation: Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

    X
  • Andre J. Marozsan,

    Affiliation: Progenics Pharmaceuticals, Tarrytown, New York, United States of America

    Current address: Alexion Pharmaceuticals, Cheshire, Connecticut, United States of America

    X
  • William C. Olson,

    Affiliation: Progenics Pharmaceuticals, Tarrytown, New York, United States of America

    X
  • Jun Zhu,

    Affiliation: Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

    X
  • Frederic D. Bushman mail

    bushman@mail.med.upenn.edu

    Affiliation: Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America

    X
  • Published: October 10, 2012
  • DOI: 10.1371/journal.pone.0046966

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.